Net Present Value Model: F. Hoffmann-La Roche Ltd’s Tiragolumab
Powered by
Unlock hidden opportunities in the NPV industry
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd’s Tiragolumab report and make more profitable business decisions.
Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development.
Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
F. Hoffmann-La Roche Ltd’s Tiragolumab Drug Details:
Tiragolumab (RG-6058, MTIG-7192A, anti-TIGIT) is under development for the treatment of advanced or metastatic hepatocellular carcinoma (HCC), melanoma, bladder cancer, renal cell carcinoma, advanced rectal cancer, advanced or metastatic solid tumors, head and neck squamous cell carcinoma (SCCHN) involving the oropharynx, oral cavity, larynx, or hypopharyngeal cancers, metastatic esophageal squamous cell carcinoma, gastroesophageal junction carcinomas, triple negative breast cancer, B-Cell Non-Hodgkin Lymphoma, locally advanced, recurrent, or metastatic incurable tumors, adenocarcinoma of the cervix, small-cell lung cancer, brain metastases, non-squamous NSCLC, HER2 negative breast cancer and non-small cell lung cancer. The drug candidate is administered as an intravenous (IV) infusion. It acts by targeting TIGIT protein.It was also under development for the treatment of relapsed/refractory multiple myeloma, gastric cancer or adenocarcinoma of gastroesophageal junction, relapsed/refractory B-cell non-Hodgkin lymphoma
Report Coverage
GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.
Quick View – Tiragolumab NPV Data | |||
Drug Name |
|
||
Administration Pathway |
|
||
Therapeutic Areas |
|
||
Key Manufacturers |
|
||
Drug Development Status |
|
Reasons to Buy
- Obtain a better understanding of the quantitative value of Net Present Value Model: F. Hoffmann-La Roche Ltd’s Tiragolumab.
- Access another data source to use in the valuation of Net Present Value Model: F. Hoffmann-La Roche Ltd’s Tiragolumab.
- Create or support internal NPV models to improve accuracy.
- Understand a drug’s expected profit, considering revenue and cost forecasts leveraging public and proprietary data sets.
Scope
- Drug Name
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
- Patent law
- Known and Projected regulatory approval processes
- Cash flows
- Potential applicable patients
- Drug margins
- Company expenses
- Pricing estimates
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Frequently asked questions
- All drug sales and forecasts within NPV Model are calculated in our proprietary company based models . In these models, Analyst Consensus forecasts are built by using company-specific broker reports to create the sales forecasts for each Drug and Segment.
- Sales and forecasts are not indication-specific where drugs are approved , or in development, for multiple indications. Please refer to GlobalData’s Disease Analysis reports for indication-specific sales forecasts.
- Risk-adjusted NPVs use GlobalData’s LoA and PTSR for the indication in the highest development stage. Please refer to the Likelihood of Approval methodology for more details on this content.
GlobalData’s NPV Model is a premium model providing a fully-interactive forecasting and valuation tool, driven by Analyst Consensus estimates, enabling users to analyze and customize valuations for pharmaceutical assets including drugs or segments. The tool provides 17-year drug forecasts from companies with sales forecast data in the pharmaceutical industry, including established global firms and emerging biotechs, which allows access to critical information to facilitate strategic decision making around pharmaceutical assets
The NPV Model includes a forecasted Revenue Model, followed by a proprietary Patent Expiry Model, Operating Profit Model, Net Profit (apply Tax rate) and Discounted Cash Flow (apply Discount rates), to derive Net Present Value (NPV) for a chosen pharmaceutical asset
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.